Business Context and Reporting Period
This Form 8-K is a current report filed by GlycoMimetics, Inc. (not Crescent Biopharma, Inc., as indicated in the metadata) on August 2, 2023. The filing serves to announce the Company's financial results for the second quarter ended June 30, 2023. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the filing text itself.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that the Company has issued a press release containing the second-quarter 2023 financial results.
Guidance, Outlook, and Risks
The text does not include management commentary, guidance, outlook, or specific risk factors. It notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is GlycoMimetics, Inc. (Ticker: GLYC), not Crescent Biopharma, Inc.
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are absent from this 8-K cover document.
- Confirm the reporting period is the quarter ended June 30, 2023.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act per the disclaimer in Item 2.02.